Original articleRandomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Section snippets
Materials and Methods
This phase 3 randomized, multicenter clinical trial was conducted by the DRCR.net at 52 clinical sites in the United States. The study adhered to the tenets of the Declaration of Helsinki. The protocol and informed consent forms were compliant with the Health Insurance Portability and Accountability Act and approved by multiple institutional review boards. Each study participant gave written informed consent before participation in the study. Study oversight was provided by an independent data
Results
Between March of 2007 and December of 2008, 691 study participants (mean age 63±10 years; 44% women) were enrolled, 163 (24%) with 2 study eyes. The mean baseline visual acuity letter score in study eyes was 63±12 (∼20/63±2.4 lines), and the mean OCT central subfield retinal thickness was 405±134 μm. The 854 study eyes were assigned to either sham + prompt laser (n=293), ranibizumab + prompt laser (n=187), ranibizumab + deferred laser (n=188), or triamcinolone + prompt laser (n=186). The
Discussion
In this randomized clinical trial, intravitreal ranibizumab, either with prompt or deferred (≥24 weeks) focal/grid laser, resulted in superior visual acuity and OCT outcomes compared with focal/grid laser treatment without ranibizumab at both 1 and 2 years of follow-up. Approximately half of the eyes treated with ranibizumab had substantial visual acuity improvement (≥10 letter gain from baseline), whereas approximately 30% gained ≥15 letters, equivalent to 3 lines on the eye chart, a reduction
References (26)
- et al.
The Wisconsin Epidemiologic Study of Diabetic RetinopathyIV: Diabetic macular edema
Ophthalmology
(1984) - et al.
The 14-year incidence of visual loss in a diabetic population
Ophthalmology
(1998) - et al.
Ten-year incidence of visual loss in a diabetic population
Ophthalmology
(1994) - et al.
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopaty and tumors
J Bio Chem
(1999) - et al.
A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol
Am J Ophthalmol
(2003) - et al.
Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial
Ophthalmology
(2006) - et al.
Intravitreal triamcinolone for refractory diabetic macular edema
Ophthalmology
(2002) Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1
Arch Ophthalmol
(1985)A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
Ophthalmology
(2008)- et al.
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
N Engl J Med
(1994)
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals
Ophthalmology
Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Ophthalmology
Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema
Arch Ophthalmol
Cited by (1243)
Proliferative diabetic retinopathy: Role of bevacizumab in decreasing the occurrence of vitreous hemorrhage after panretinal photocoagulation
2024, Journal Francais d'OphtalmologieThe Association of Intravitreal Anti-VEGF Injections With Kidney Function in Diabetic Retinopathy
2023, Ophthalmology ScienceFrom randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema
2023, Progress in Retinal and Eye ResearchResearch trends of worldwide ophthalmologic randomized controlled trials in the 21st century: A bibliometric study
2023, Advances in Ophthalmology Practice and ResearchShort-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema
2024, BMC Ophthalmology
Manuscript no. 2010-112.
The most recently published list of the DRCR.net investigators and staff who participated in this study is available at www.drcr.net.
Correspondence: Protocol I Correspondence, Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647. E-mail: [email protected]
This article contains online-only material. The following should appear online-only: Table 1, Table 2, Table 3, Table 4, Table 6, Table 7, Table 9, Table 10, Table 12, Table 13, Table 14, Table 16, Table 18, Table 19; Figure 1, Figure 2, Figure 5, Figure 7, Figure 8; Appendix 1 Diabetic Retinopathy Clinical Research Network Laser-Ranibizumab-Triamcinlone Study Treatment, Appendix 2, Appendix 3, Appendix 4, Appendix 5. (website).
Financial Disclosure(s): Supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human ServicesEY14231, EY14229, and EY018817.
The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the manuscript but not directly in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation of the manuscript. Genentech provided the ranibizumab for the study, and Allergan, Inc., provided the triamcinolone for the study. In addition, Genentech and Allergan, Inc., provided funds to the DRCR.net to defray the study's clinical site costs. As described in the DRCR.net Industry Collaboration Guidelines (available at www.drcr.net), the DRCR.net had complete control over the design of the protocol, the ownership of the data, and all editorial content of presentations and publications related to the protocol. A complete list of all DRCR.net investigator financial disclosures can be found at www.drcr.net.
The lead author(s) have made the following disclosure(s): Scott M. Friedman: Sirion Therapeutics (S), MacuSight (S), Pfizer (S), Vitreoretinal Technologies (S), Allergan (S), EMMES Corporation (S). Ingrid U. Scott: Genentech (C). Lloyd P. Aiello: Genentech (C). Susan B. Bressler: GlaxoSmithKline (C). Frederick L. Ferris III; Bausch & Lomb (P).
Neil M. Bressler:
Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution (e.g., the School of Medicine) that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the projects(s).
Dr. Neil M. Bressler is Principal Investigator of grants at The Johns Hopkins University sponsored by the following entities (not including the National Institutes of Health): Allergan, Bausch & Lomb, Carl Zeiss Meditec, EMMES Corporation, Genentech, Lumenis, Notal Vision Ltd.,* Novartis, QLT, Regeneron, Steba Biotech, Abbott Medical Optics, ForSight Labs, LLC, and Genzyme Corporation. Dr. Susan B. Bressler's consulting arrangement with Notal Vision in connection with Dr. Neil M. Bressler's role as principal investigator on a Notal Vision-sponsored research grant has been reviewed and managed by The Johns Hopkins University School of Medicine in accordance with its conflict of interest policy.
- ⁎
The members of the DRCR Network who participated in this protocol are listed in Appendix 5.